LaderM. Long-term side effects of antipsychotic medication.Clinical Risk1998; 4: 173–7
2.
JusicN, LaderM. Post-mortem antipsychotic drug concentrations and unexplained deaths.Br J Psychiatr1994; 165: 787–91
3.
ReinertRE, HermannCG. Unexplained deaths during chlorpromazine therapy.J Nerv Ment Dis1960; 131: 435–42
4.
Working Group of the Royal College of Psychiatrists’ Psychopharmacology Sub-group.The Association between Antipsychotic Drugs and Sudden Death (Council Report CR 57).London: Royal College of Psychiatrists,1997
5.
FerrierN. Torsade de Pointes and sudden death. In: HaddadP, DursunS, DeakinB (eds.) Adverse Syndromes and Psychiatric Drugs: A Clinical Guide.Oxford: Oxford University Press,2004
6.
GlassmanAH, BiggerJT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.Am J Psychiatry2001; 158: 1774–82
7.
TitierK, GirodetP-O, VerdouxH. Atypical antipsychotics. From potassium channels to torsade de pointes and sudden death.Drug Safety2005; 28: 35–51
8.
TaylorDM. Antipsychotics and QT prolongation.Acta Psychiatr Scand2003; 107: 85–95
9.
ReillyJG, AyisSA, FerrierIN. Thioridazine and sudden unexplained death in psychiatric inpatients.Br J Psychiatry2002; 180: 515–22
10.
HennessyS, BilkerWB, KnaussJS. Cardiac arrest and ventricular arrhythmia in patient taking antipsychotic drugs: cohort study using administrative data.BMJ2002; 325: 1070–2
11.
RayWA, MeredithS, ThapaB. Antipsychotics and the risk of sudden cardiac death.Arch Gen Psychiatry2001; 58: 1161–7
12.
HaddadPM, AndersonIM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.Drugs2002; 62: 1649–71
13.
LindstromE, FardeL, EberhardJ, HaverkampW. QTc interval prolongation and antipsychotic drug treatments: focus on sertindole.Int J Neuropsychopharmacol2005; 8: 615–29
14.
KohenD. Neuroleptic malignant syndrome. In: HaddadP, DursunS, SeakinB (eds.) Adverse Syndromes and Psychiatric Drugs: A Clinical Guide.Oxford: Oxford University Press,2004
AditanjeeYAA, MathewsT. Epidemiology of neuroleptic malignant syndrome.Clinical Neuropharmacol1999; 22: 151–8
17.
American Psychiatric Association.Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition Text revision (DSM-IV-TR).Washington: American Psychiatric Association,2000
18.
ShalevA, MunitzH. The neuroleptic malignant syndrome: agent and host interaction.Acta Psychiatr Scand1986; 73: 337–47
CaroffSN, MannSC, KeckPE. Specific treatment of the neuroleptic malignant syndrome.Biol Psychiat1998; 44: 378–81
21.
BristowMF, KohenD. Predicting the effects of re-challenge with antipsychotics following NMS. A review of cases from a Neuroleptic Malignant Syndrome database.Brain Pharmacol2002; 1: 181–7
22.
AllisonDB, MentoreJL, HeoM. Antipsychotic-induced weight gain: a comprehensive research synthesis.Am J Psychiatry1999; 156: 1686–96
23.
MelkerssonK, DahlM-L. Adverse metabolic effects associated with atypical antipsychotics. Literature review and clinical implications.Drugs2004; 64: 701–23
